Bayer
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Bayer sits in the top decile of US sponsors by registered trial count (#58 of 15,742 sponsors by registered trial count).
Bayer: 591 sponsored US clinical trials, 21 recruiting.
Bayer sponsors 591 registered US clinical trials on ClinicalTrials.gov, 21 of them currently recruiting, and 494 completed. 172 of these trials are in Phase 3-4 (later-stage) and 237 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sunscreening Agents, with 17 trials.
Top-decile sponsor footprint
Bayer ranks in the top decile of sponsors by registered trial count (#58 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
494 of 552 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
591 total, page 9 of 12
Actual Use Trial of Naproxen Sodium
NCT01427803
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
NCT01411410
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer
NCT01392521
Self Selection Trial of Naproxen Sodium
NCT01383486
Evaluate Onset of Action of a Fast Release Aspirin
NCT01420094
BAY81-8973 Pediatric Safety and Efficacy Trial
NCT01311648
Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium
NCT01389284
Essure Transvaginal Ultrasound (TVU) Study
NCT01327105
Gadobutrol Enhanced MRA of the Supra-aortic Vessels
NCT01344447
Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study
NCT01348880
Safety Trial of Naproxen Sodium/ Diphenhydramine
NCT01365052
Gadobutrol Enhanced MRA of the Renal Arteries
NCT01344460
Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension
NCT01303783
Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity
NCT01339104
Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics
NCT01318265
Effect of Rifampin on the Pharmacokinetics of BAY73-4506
NCT01322438
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
NCT01234337
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
NCT01289821
LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study
NCT01254292
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
NCT01271712
Combination With Gemcitabine in Advanced Pancreatic Cancer
NCT01251640
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
NCT01233258
Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies
NCT01335256
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)
NCT01228513
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
NCT01145859
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
NCT01065051
Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
NCT01184820
Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain
NCT01280591
Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters.
NCT01179334
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
NCT01188252
Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer
NCT01187615
Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection
NCT01069900
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
NCT01106352
Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.
NCT04534491
Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients
NCT01049022
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
NCT01104584
Evaluate Analgesic Efficacy of Fast Release Aspirin
NCT01122602
Evaluate Analgesic Efficacy of Fast Release Aspirin
NCT01117636
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
NCT01065454
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
NCT01103323
A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
NCT01064037
BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
NCT01065077
A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
NCT01067859
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
NCT01067976
Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin
NCT01081353
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.
NCT01031459
Contrast-enhanced MRI in Children 2 Months to <2 Years
NCT00937391
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
NCT01029340
Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.
NCT01043523
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
NCT00962611
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 130 |
| Phase 2 | 107 |
| Phase 3 | 144 |
| Phase 4 | 28 |
What is open in the Bayer pipeline
21 recruiting of 591 indexed (4% open); 494 completed (84%).
Phase mix: 172 late (III/IV) vs 237 early (I/II) (balanced across stages).
Top condition: Sunscreening Agents (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bayer: open-pipeline peers nationwide
Peers matched on 591 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Bayer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 591 trials (± recruiting share)
- Janssen Research & Development · 593 trials · 11% recruiting
- City of Hope Medical Center · 582 trials · 29% recruiting
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Bausch Health Americas · 4% recruiting · 168 trials
- Harvard Pilgrim Health Care · 4% recruiting · 28 trials
- Sumitomo Pharma America · 4% recruiting · 168 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
Related
What to do with this Bayer page
591 registered trials is a research-attention snapshot, not an endorsement of Bayer or any single study.
- 21 of Bayer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sunscreening Agents is the condition Bayer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sunscreening Agents trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bayer pipeline card: 591 registered trials from official public datasets.Report a data error.